Skip to Content

Zai Lab Ltd ADR Repr 1 Shs ZLAB

Morningstar Rating

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

Business Wire Apr 15, 2024 11:30am
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities

Business Wire Apr 11, 2024 11:30am
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Business Wire Apr 2, 2024 11:30am
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

Business Wire Apr 1, 2024 11:30am
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Business Wire Mar 27, 2024 1:29pm
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Business Wire Mar 13, 2024 11:05pm
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Business Wire Mar 6, 2024 9:01pm
Zai Lab Announces Participation in March Investor Conference

Business Wire Mar 6, 2024 12:30pm
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Business Wire Feb 27, 2024 9:05pm
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024

Business Wire Jan 25, 2024 9:15pm
Airbnb, Tesla stocks rise, Manchester United, Softbank shares fall and other stocks on the move

MarketWatch Sep 5, 2023 4:55pm
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

MarketWatch Sep 5, 2023 12:13pm
Argenx Shares Hit 52-Week High After Positive Vyvgart Hytrulo Trial Results

Global News Select Jul 17, 2023 2:49pm
Argenx, Zai Lab Shares Rise After Positive Trial Results for Vyvgart Hytrulo

Global News Select Jul 17, 2023 10:55am

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.